In low grade glioma with activation of the MEK/ERK pathway, aberrations in BRAF or NF1 MEK inhibition with trametinib or selumetinib revealed promising activity in pediatric patients [52, 53]. This evidence concerns the gene NF1 and central nervous system cancer.